Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults - Novel Health Care Strategies for Melanoma in Children, Adolescents and Young Adults (MELCAYA)
Status: Recruiting
Location: See all (6) locations...
Study Type: Observational
SUMMARY
The primary objective of this study is the identification of environmental and genetic factors involved in the risk and progression of melanoma in children, adolescents and young adults (CAYA). The secondary objectives are to generate a model integrating the genetic and environmental factors to estimate the risk of developing melanoma and improve the primary prevention of melanoma through evidence-based interpretation of environmental risk.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 30
View:
• confirmed melanoma
• age until 30 years old
Locations
Other Locations
Germany
Leibniz Research Institute for Environmental Medicine
ACTIVE_NOT_RECRUITING
Düsseldorf
Italy
University of Florence
ACTIVE_NOT_RECRUITING
Florence
Istituto Nazionale del Tumori
ACTIVE_NOT_RECRUITING
Milan
Poland
Medical University of Gdánsk
RECRUITING
Gdansk
Spain
Hospital Clínic de Barcelona
RECRUITING
Barcelona
Sweden
Karolinska Institute
RECRUITING
Solna
Contact Information
Primary
Ines B Brecht, MD, PhD
ines.brecht@med.uni-tuebingen.de
+49707183773
Backup
Christopher Schroeder, MD
christopher.schroeder@med.uni-tuebingen.de
Time Frame
Start Date: 2024-01-01
Estimated Completion Date: 2026-05-31
Participants
Target number of participants: 200
Treatments
Classic melanoma
Classic malignant melanoma under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
Spitzoid melanoma
Spitzoid melanoma under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
Other melanoma
Other melanoma as melanoma on congenital nevi under the age of 30 years For patients with available biospecimen, the germline genome, transcriptome and in selected cases tumour normal exomes will be sequenced.
Related Therapeutic Areas
Sponsors
Collaborators: Hospital Clinic of Barcelona, Medical University of Gdansk, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Karolinska University Hospital, Princess Maxima Center for Pediatric Oncology, Leibniz Research Institute for Environmental Medicine Düsseldorf, University Of Perugia
Leads: University Hospital Tuebingen